Advanced Accelerator Applications USA, a Novartis company
Lutathera is indicated to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, which include foregut, midgut and handout neuroendocrine tumors in adults.
The pharmaceutical agent works by binding somatostatin receptors with the highest affinity for subtype 2 receptors and are expressed on the surface of GEP-NET cells. Lutatheria is internalized into somatostatin receptor-bearing cells where beta radiation is delivered. The radiation then causes damage in somatostatin receptor-positive cells and neighboring cells.
Serious side effects include radiation exposure, bone marrow problems, secondary bone marrow and blood cancers, kidney problems, liver problems, hormonal gland problems and fertility problems. Some of the most common and most serious side effects of Lutathera are vomiting, nausea, decreased blood cell counts, increased liver enzymes, decreased blood potassium levels and increased glucose in the bloodstream.
Filed Under: Drug Discovery, Drug Discovery and Development, Neurological Disease, Oncology, Orphan Drugs